Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
OXFORD, United Kingdom, March 30, 2017 -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr. Glyn Edwards, Chief Executive Officer, will present at the Needham Healthcare Conference, 5 April 2017 at 11:20am EDT in New York City.
A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Therapeutics | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: +44 (0)1235 443 951 | |
| Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP | ||
| (Nominated Adviser) | ||
| Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7213 0880 | |
| N+1 Singer | ||
| (Broker) | ||
| Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 | |
| MacDougall Biomedical Communications | ||
| (US media contact) | Tel: +1 781 235 3060 | |
| Karen Sharma | [email protected] | |
| Consilium Strategic Communications | ||
| (Financial public relations, UK) | Tel: +44 (0)20 3709 5700 | |
| Mary-Jane Elliott / Sue Stuart / | [email protected] | |
| Jessica Hodgson / Lindsey Neville | ||
-END-
